Health IT

Google Glass: More enterprise than consumer?

After wearing Google Glass for a month, Kyle Samani, co-founder of Pristine, says that the unit is useless as a consumer device. “The social awkwardness doesn’t justify the value of wearing it,” he said. “The smart phone is really good at what it does and Glass isn’t a substitute.” Samani sees enterprise apps as the […]

After wearing Google Glass for a month, Kyle Samani, co-founder of Pristine, says that the unit is useless as a consumer device.

“The social awkwardness doesn’t justify the value of wearing it,” he said. “The smart phone is really good at what it does and Glass isn’t a substitute.”

Samani sees enterprise apps as the real value of the invention.

“Construction workers, surgeons, it makes sense for people doing something hands on,” he said.

Both he and co-founder Patrick Kolencherry are Google beta developers. They received one unit as part of the initial rollout to that group. They are also buying units from people to use in their startup: building software for operating rooms.

“People are open to the idea of us taking it off their hands,” he said. “People have started playing with it and realized that unless you have enterprise domain specific knowledge, it is useless.”

He is also hoping to get a batch of units from Google once the company has completed a pilot project with a hospital.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

“We are not not just making a game or a shopping app,” he said. “Our pitch to Google will be ‘Please give us more units – we can save people’s lives.'”
[Image from flickr user Carbrera Luengo]

Topics